KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Multi-Center Randomized Trial Evaluating the Safety and Effectiveness of the Instylla Hydrogel Embolic System (HES) for Vascular Occlusion of Hypervascular Tumors. PMID 42409306 · J Vasc Interv Radiol · 2026-Jul-06 The study is a randomized trial of a device (hydrogel embolic system) for tumor embolization. It does not involve a drug intervention and does not report a time-to-event efficacy endpoint; the primary endpoints are safety (Freedom from MAE) and technical success (effectiveness). It is therefore ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Coenzyme Q10 as an adjunctive strategy to reduce paclitaxel-induced toxicities in breast cancer: a randomized controlled trial. PMID 42401951 · BMC Pharmacol Toxicol · 2026-Jul-04 The study is an original, randomized, oncology trial with a drug intervention, but the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata. Furthermore, while a time-to-event measure (time-to-onset of neuropathy) is reported, it is a secondary endpoint related to toxicity, not a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) required for inclusion in the Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Preoperative whey protein supplementation for postoperative nausea, vomiting and recovery in well-nourished gynecologic tumor patients: a randomized controlled trial. PMID 42401710 · Sci Rep · 2026-Jul-04 The study is a randomized trial in gynecologic oncology patients (human, oncology). It is an original primary result report. However, it is excluded because: 1) the primary endpoint is incidence of postoperative nausea and vomiting (PONV), a binary outcome, not a time-to-event endpoint (OS, PFS, DFS, etc.) with KM/HR; 2) the intervention is a nutritional supplement (whey protein), not a systemic drug (chemotherapy, targeted therapy, immunotherapy, etc.); 3) the trial phase is not specified, and it does not appear to be a definitive Phase III/IIIb trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Combined indwelling pleural catheter with thoracoscopic talc poudrage for malignant pleural effusion management: a randomized non-inferiority trial. PMID 42399890 · BMC Pulm Med · 2026-Jul-04 The study is a randomized trial in oncology (malignant pleural effusion) with original results, but it is not a Phase III/IIIb or Phase II/III trial (phase unclear from text, not explicitly stated as such), does not have a drug-containing intervention (comparing procedural techniques: IPC + TTP vs. TTP alone), and does not have a primary/key secondary time-to-event efficacy endpoint (primary endpoint is pleurodesis success rate at 12 weeks, a binary outcome, not time-to-event).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of opioid-free anesthesia on postoperative anxiety in patients undergoing modified radical mastectomy for breast cancer: a randomized controlled trial. PMID 42399751 · BMC Anesthesiol · 2026-Jul-04 The study is a randomized trial in breast cancer patients, but the intervention is a perioperative anesthetic regimen (opioid-free vs. opioid-based), not a systemic oncology drug treatment. The primary endpoint is a patient-reported anxiety score at 24 hours, not a time-to-event efficacy endpoint like OS or PFS. Therefore, it does not meet the criteria for a drug intervention or a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A carotenoid-rich functional tomato sauce (OsteoCol®) reduces liver fat content in adults with metabolic dysfunction-associated steatotic liver disease: a randomized clinical trial. PMID 42397564 · Eur J Nutr · 2026-Jul-03 The study is a randomized, placebo-controlled trial of a functional food (tomato sauce) for metabolic dysfunction-associated steatotic liver disease (MASLD), a non-oncologic condition. It does not involve a drug intervention, does not report a time-to-event efficacy endpoint (OS, PFS, etc.), and does not specify a Phase III/IIIb or Phase II/III trial design.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of aspirin on healthspan in community-dwelling older adults: the ASPirin in reducing events in the elderly study. PMID 42497096 · Age Ageing · 2026-Jul-02 The study is not an oncology trial. The primary endpoint is a composite healthspan outcome (cardiovascular disease, diabetes, dementia, cancer, or death) in a general older adult population for primary prevention, not a trial of a drug for the treatment of a specific human malignant neoplasm.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ablative radiotherapy in castration-resistant prostate cancer. PMID 42389925 · BJU Int · 2026-Jul-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a post-hoc analysis of the RIDTS trial. PMID 42389836 · Haematologica · 2026-Jul-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia. PMID 42389818 · Haematologica · 2026-Jul-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Low- vs standard-dose regimens as induction for pediatric AML: a multicenter, randomized noninferiority trial. PMID 41812214 · Blood · 2026-Jul-02 The record meets most eligibility criteria but lacks explicit evidence of being a Phase III/IIIb or Phase II/III trial, which is a required criterion for inclusion. Metadata does not confirm the trial phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Surveillance vs Standard Surgery and Cost-Effectiveness After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: Secondary Analysis of a Randomized Clinical Trial. PMID 42507446 · JAMA Netw Open · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Concurrent chemoradiotherapy with or without simultaneous integrated boost for unresectable stage III non-small-cell lung cancer: a randomized phase II trial with exploratory EGFR and PD-L1 analyses. PMID 42456525 · Cancer Genet · 2026-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study. PMID 42387482 · BMC Med · 2026-Jul-01 The report is an original, randomized, oncology trial with a drug intervention and time-to-event endpoints, but it is a secondary analysis (renal injury) rather than the primary or key secondary efficacy analysis of the trial. Additionally, the trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided information.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial. PMID 42385761 · Lancet Oncol · 2026-Jul-01 The trial is a Phase II study with a primary endpoint of pathological complete response, which is not a time-to-event efficacy endpoint. No Kaplan-Meier or hazard ratio data for OS, PFS, DFS, EFS, RFS, or TTP are reported.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer. PMID 42385609 · Gynecol Oncol · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial. PMID 42385345 · Transl Oncol · 2026-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
From Cardioprotection to Trial Design: Rethinking Cardiac Safety in Oncology. PMID 42384221 · Curr Heart Fail Rep · 2026-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib. PMID 42319132 · Cancer · 2026-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours. PMID 42240214 · Curr Opin Oncol · 2026-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effects of a trans-theoretical model-based structured psychoeducational continuing care program in adult patients with acute Leukemia. PMID 42224028 · Physiol Int · 2026-Jul-01 The study is a randomized oncology trial reporting overall survival as a time-to-event endpoint. However, it is ineligible because it does not include a drug-containing intervention (the intervention is a psychoeducational program) and the formal trial phase (III/IIIb or II/III) is not established in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial. PMID 42113507 · JAMA Intern Med · 2026-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Sentinel Lymph Node Biopsy for Patients With cN1 HR+/HER2- Breast Cancer and Palpable Adenopathy: A Nonrandomized Clinical Trial. PMID 42090164 · JAMA Surg · 2026-Jul-01 The study is a nonrandomized clinical trial evaluating a surgical procedure (SLNB) for breast cancer. It is not a randomized trial, is not Phase III (it is a feasibility study), and lacks a drug intervention or a primary time-to-event efficacy endpoint as defined (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis. PMID 42077070 · Cancer Prev Res (Phila) · 2026-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial. PMID 41927282 · J Nucl Med · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer. PMID 41870279 · Clin Cancer Res · 2026-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Endoscopic Application of Tranexamic Acid and Sucralfate in Upper Gastrointestinal Bleeding: A Randomized Controlled Trial. PMID 41860133 · Clin Transl Gastroenterol · 2026-Jul-01 The study is a randomized trial of drug interventions (tranexamic acid and sucralfate) for upper gastrointestinal bleeding, but it is not an oncology study. The primary endpoint is rebleeding rate, a binary outcome, not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, or TTP.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Effect of Preoperative Tranexamic Acid on Blood Transfusions in Geriatric Hip Fracture Surgery: A Randomized Controlled Trial. PMID 41837612 · J Orthop Trauma · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Adjuvant Chemotherapy After Curative Intent Resection of Ampullary Cancer (ADAPTA): Study Protocol for a Pan-European Prospective Multicenter Double Single Arm Trial. PMID 41812337 · Am J Clin Oncol · 2026-Jul-01 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial. PMID 41801147 · Cancer Prev Res (Phila) · 2026-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up. PMID 41712503 · J Natl Cancer Inst · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer. PMID 41649873 · Clin Cancer Res · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study. PMID 41568521 · Haematologica · 2026-Jul-01 The study is an oncology Phase III randomized trial with a drug intervention and presents original results. However, the primary endpoint of the IMerge study is 8-week RBC transfusion independence (a categorical response endpoint), not a time-to-event outcome like OS, PFS, DFS, etc. This specific report focuses on secondary/quality-of-life analyses (patient-reported outcomes), which are excluded per the criteria. There is no mention of Kaplan-Meier curves or hazard ratios for a time-to-event endpoint in this abstract.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Progression of Dupuytren Contracture: A Randomized Controlled Trial Comparing Surgery, Needle Fasciotomy, and Collagenase Injection. PMID 41334972 · Plast Reconstr Surg · 2026-Jul-01 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effects of Nutritional Interventions on Quality of Life in Patients with Nasopharyngeal Carcinoma Undergoing Radiation Therapy Based on Dynamic Nutritional Risk Screening and Assessment: An Open-Label Single-Center Randomized Phase 3 Trial. PMID 41325872 · Int J Radiat Oncol Biol Phys · 2026-Jul-01 The study is a randomized, Phase III trial in oncology patients, but it evaluates nutritional interventions (not a drug-containing intervention) and uses quality-of-life and nutritional status as endpoints, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Combination of Neuronavigation-Guided Focused Ultrasound and Bevacizumab for Patients With Recurrent Glioblastoma: A Pilot Study. PMID 41283685 · Neurosurgery · 2026-Jul-01 The record describes a single-arm, open-label pilot study, not a randomized trial. It is explicitly labeled as a 'pilot trial' and does not report Phase III/IIIb or Phase II/III evidence. While it is an oncology study with a drug intervention and a primary time-to-event endpoint (PFS), it fails the critical eligibility criteria for being a randomized Phase III/IIIb or Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical trials in cancer theranostics with potential near-term impact on clinical practice. PMID 39873742 · Br J Radiol · 2026-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Postoperative Exercise Training in Patients With Colorectal Liver Metastases: A Randomized Controlled Trial. PMID 39523954 · Ann Surg · 2026-Jul-01 The trial is a randomized, oncology study in humans evaluating postoperative exercise in colorectal liver metastases patients receiving chemotherapy. It reports primary safety outcomes and secondary efficacy/quality-of-life endpoints. However, it does not meet the core eligibility criteria: it is not explicitly a Phase III or definitive drug efficacy trial (the phase is not stated, and the focus is exercise intervention, not a specific drug regimen), and no time-to-event efficacy endpoint (like OS or PFS) is reported as primary or key secondary. The primary endpoint is safety (serious adverse events).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Exploratory Time-Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non-Deficient or Unknown Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO-2 Trial. PMID 42502892 · Int J Urol · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Long-Term Dietary Changes and Mortality among Participants of a Whole Food Plant-Based Pilot Study for Metastatic Breast Cancer. PMID 42473551 · Curr Dev Nutr · 2026-Jul The study is a long-term follow-up of a small randomized pilot study of a dietary intervention (whole food plant-based diet) for metastatic breast cancer. While it is oncology, human, randomized, and reports survival counts, it is excluded because: (1) It is not a Phase III/IIIb or Phase II/III trial (it is a pilot/feasibility study); (2) The intervention is dietary, not drug-containing; (3) The survival data is reported only as descriptive mortality counts at a single time point, not as a formal time-to-event analysis (e.g., Kaplan-Meier, log-rank, hazard ratio).
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Hypertrophy-Oriented Resistance Training on Muscle Mass and Quality of Life in Patients with Unresectable Pancreatic Cancer (HY-PANC): Study Protocol for a Randomized Controlled Trial. PMID 42461827 · Curr Protoc · 2026-Jul 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Multivitamin supplementation and COVID-19 incidence and symptom severity in the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized trial. PMID 42385272 · Am J Clin Nutr · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Common EGFR Mutations Treated With Afatinib. PMID 42381340 · Thorac Cancer · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
ELECLA trial: final results of perioperative chemotherapy with fluoropyrimidine and oxaliplatin in mismatch repair proficient locally advanced colon cancer. PMID 42378717 · ESMO Open · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs. Sunitinib) for Advanced Renal Cell Carcinoma. PMID 42373289 · Anticancer Res · 2026-Jul The record describes a Bayesian reanalysis of subgroup data from the CLEAR trial, not the primary or definitive results of the original Phase III randomized trial. The phase of the original trial is not explicitly stated in the provided metadata. The report type is a secondary analysis, not a primary or final result publication.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial. PMID 42372744 · Lancet Oncol · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A study protocol for a randomised controlled trial evaluating the safety and efficiency of the YEARS algorithm versus computed tomography pulmonary angiography only for suspected acute pulmonary embolism in patients with cancer: the Hydra Study. PMID 42365759 · Thromb Res · 2026-Jul 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial. PMID 42350643 · Nat Med · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease. PMID 42345857 · Future Oncol · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Model-Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer. PMID 42337921 · Clin Transl Sci · 2026-Jul The record describes a Phase I PK study with PopPK modeling and simulations to support Phase 3 dose selection. While it is a randomized, drug-intervention oncology study, it reports only pharmacokinetic outcomes (bioavailability, exposure), not time-to-event efficacy endpoints like OS or PFS with Kaplan-Meier or HR. Therefore, it does not meet the core requirement for a time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -